We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » GPhA, BIO ‘Deeply Troubled’ By Compounding Clarity Act
GPhA, BIO ‘Deeply Troubled’ By Compounding Clarity Act
September 24, 2013
The recently proposed Compounding Clarity Act would allow compounders to copy unapproved drugs, potentially “denigrating” the FDA’s approval process, as well as “incentives for innovation” such as Hatch-Waxman Act exclusivity, the Generic Pharmaceutical Association (GPhA) and Biotechnology Industry Organization (BIO) assert.